High content analysis of γ-secretase activity reveals variable dominance of presenilin mutations linked to familial Alzheimer's disease

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1783, Issue 8, 2008, Pages 1551-1560

  Florean, Cristina ^a,b   Zampese, Enrico ^a   Zanese, Marion ^b,c   Brunello, Lucia ^a   Ichas, François ^b,c   De Giorgi, Francesca ^b,c   Pizzo, Paola ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b INSERM   (France)

^c FLUOFARMA   (France)

Author keywords

Secretase assay; Alzheimer's disease; Automated flow cytometry; High content analysis; Presenilin; Recombinant probe

Indexed keywords

FLUORESCENT DYE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GREEN FLUORESCENT PROTEIN; PRESENILIN; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE; FLOW CYTOMETRY; FLUORESCENT DYES; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MUTATION; PRESENILINS; RECOMBINANT PROTEINS;

EID: 46549088669     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.03.012     Document Type: Article

References (44)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
2. Sisodia S.S., and St George-Hyslop P.H. g-Secretase, Notch, Ab and Alzheimer's disease: where do the presenilins fit in?. Nat. Rev., Neurosci. 3 (2002) 281-290
3. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J. Mol. Neurosci. 23 (2004) 105-114
4. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-b oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002) 552-557
5. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
6. Raychaudhuri M., and Mukhopadhyay D. AICD and its adaptors - in search of new players. J. Alzheimer's Dis. 11 (2007) 343-358
7. Sastre M., Steiner H., Fuchs K., Capell A., Multhaup G., Condron M.M., Teplow D.B., and Haass C. Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. 2 (2001) 835-841
8. Zhao G., Mao G., Tan J., Dong Y., Cui M.Z., Kim S.H., and Xu X. Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. J. Biol. Chem. 279 (2004) 50647-50650
9. Zhao G., Cui M.Z., Mao G., Dong Y., Tan J., Sun L., and Xu X. gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. J. Biol. Chem. 280 (2005) 37689-37697
10. Zhao G., Tan J., Mao G., Cui M.Z., and Xu X. The same gamma-secretase accounts for the multiple intramembrane cleavages of APP. J. Neurochem. 100 (2007) 1234-1246
11. Dong Y., Tan J., Cui M.Z., Zhao G., Mao G., Singh N., and Xu X. Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta46 and protecting Abeta from degradation. FASEB J. 20 (2006) 331-333
12. Kakuda N., Funamoto S., Yagishita S., Takami M., Osawa S., Dohmae N., and Ihara Y. Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. J. Biol. Chem. 281 (2006) 14776-14786
13. Iwatsubo T. The g-secretase complex: machinery for intramembrane proteolysis. Curr. Opin. Neurobiol. 14 (2004) 379-383
14. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 38 (2003) 9-12
15. Parks A.L., and Curtis D. Presenilin diversifies its portfolio. Trends Genet. 23 (2007) 140-150
16. Ertekin-Taner N. Genetics of Alzheimer's disease: a centennial review. Neurol. Clin. 25 (2007) 611-667 v
17. Lundkvist J., and Naslund J. Gamma-secretase: a complex target for Alzheimer's disease. Curr. Opin. Pharmacol. 7 (2007) 112-118
18. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., Goate A., and Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398 (1999) 518-522
19. Zatti G., Burgo A., Giacomello M., Barbiero L., Ghidoni R., Sinigaglia G., Florean C., Bagnoli S., Binetti G., Sorbi S., Pizzo P., and Fasolato C. Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium 39 (2006) 539-550
20. Giacomello M., Barbiero L., Zatti G., Squitti R., Binetti G., Pozzan T., Fasolato C., Ghidoni R., and Pizzo P. Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. Neurobiol. Dis. 18 (2005) 638-648
21. Gervais F.G., Xu D., Robertson G.S., Vaillancourt J.P., Zhu Y., Huang J., LeBlanc A., Smith D., Rigby M., Shearman M.S., Clarke E.E., Zheng H., Van Der Ploeg L.H., Ruffolo S.C., Thornberry N.A., Xanthoudakis S., Zamboni R.J., Roy S., and Nicholson D.W. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97 (1999) 395-406
22. Kaether C., Schmitt S., Willem M., and Haass C. Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic 7 (2006) 408-415
23. Zhang C., Khandelwal P.J., Chakraborty R., Cuellar T.L., Sarangi S., Patel S.A., Cosentino C.P., O'Connor M., Lee J.C., Tanzi R.E., and Saunders A.J. An AICD-based functional screen to identify APP metabolism regulators. Mol Neurodegener 2 (2007) 15
24. Dovey H.F., John V., Anderson J.P., Chen L.Z., de Saint Andrieu P., Fang L.Y., Freedman S.B., Folmer B., Goldbach E., Holsztynska E.J., Hu K.L., Johnson-Wood K.L., Kennedy S.L., Kholodenko D., Knops J.E., Latimer L.H., Lee M., Liao Z., Lieberburg I.M., Motter R.N., Mutter L.C., Nietz J., Quinn K.P., Sacchi K.L., Seubert P.A., Shopp G.M., Thorsett E.D., Tung J.S., Wu J., Yang S., Yin C.T., Schenk D.B., May P.C., Altstiel L.D., Bender M.H., Boggs L.N., Britton T.C., Clemens J.C., Czilli D.L., Dieckman-McGinty D.K., Droste J.J., Fuson K.S., Gitter B.D., Hyslop P.A., Johnstone E.M., Li W.Y., Little S.P., Mabry T.E., Miller F.D., and Audia J.E. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76 (2001) 173-181
25. Morohashi Y., Kan T., Tominari Y., Fuwa H., Okamura Y., Watanabe N., Sato C., Natsugari H., Fukuyama T., Iwatsubo T., and Tomita T. C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester). J. Biol. Chem. 281 (2006) 14670-14676
26. Shearman M.S., Beher D., Clarke E.E., Lewis H.D., Harrison T., Hunt P., Nadin A., Smith A.L., Stevenson G., and Castro J.L. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 39 (2000) 8698-8704
27. Herreman A., Serneels L., Annaert W., Collen D., Schoonjans L., and De Strooper B. Total inactivation of g-secretase activity in presenilin-deficient embryonic stem cells. Nat. Cell Biol. 2 (2000) 461-462
28. Bentahir M., Nyabi O., Verhamme J., Tolia A., Horre K., Wiltfang J., Esselmann H., and De Strooper B. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 96 (2006) 732-742
29. Micchelli C.A., Esler W.P., Kimberly W.T., Jack C., Berezovska O., Kornilova A., Hyman B.T., Perrimon N., and Wolfe M.S. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J. 17 (2003) 79-81
30. Berechid B.E., Kitzmann M., Foltz D.R., Roach A.H., Seiffert D., Thompson L.A., Olson R.E., Bernstein A., Donoviel D.B., and Nye J.S. Identification and characterization of presenilin-independent Notch signaling. J. Biol. Chem. 277 (2002) 8154-8165
31. F. Ichas, F. De Giorgi, P.V. Piazza, J. Dessolin, L. Schembri, F. Tomasello, L. Lartigue, Method for demonstration of a molecular event in a cell by means of fluorescent markers protein [French Patent No FR2857098 and World Patent Filing No WO2005/012913], (2005).
32. Edbauer D., Willem M., Lammich S., Steiner H., and Haass C. Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). J. Biol. Chem. 277 (2002) 13389-13393
33. Karlstrom H., Bergman A., Lendahl U., Naslund J., and Lundkvist J. A sensitive and quantitative assay for measuring cleavage of presenilin substrates. J. Biol. Chem. 277 (2002) 6763-6766
34. Sernee M.F., Evin G., Culvenor J.G., Villadangos J.A., Beyreuther K., Masters C.L., and Cappai R. Selecting cells with different Alzheimer's disease gamma-secretase activity using FACS. Differential effect on presenilin exon 9 gamma- and epsilon-cleavage. Eur. J. Biochem. 270 (2003) 495-506
35. Liao Y.F., Wang B.J., Cheng H.T., Kuo L.H., and Wolfe M.S. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem. 279 (2004) 49523-49532
36. Deroo B.J., and Archer T.K. Proteasome inhibitors reduce luciferase and beta-galactosidase activity in tissue culture cells. J. Biol. Chem. 277 (2002) 20120-20123
37. Kimberly W.T., Esler W.P., Ye W., Ostaszewski B.L., Gao J., Diehl T., Selkoe D.J., and Wolfe M.S. Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s). Biochemistry 42 (2003) 137-144
38. Lai M.T., Chen E., Crouthamel M.C., DiMuzio-Mower J., Xu M., Huang Q., Price E., Register R.B., Shi X.P., Donoviel D.B., Bernstein A., Hazuda D., Gardell S.J., and Li Y.M. Presenilin-1 and presenilin-2 exhibit distinct yet overlapping g-secretase activities. J. Biol. Chem. 278 (2003) 22475-22481
39. Shen J., Bronson R.T., Chen D.F., Xia W., Selkoe D.J., and Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 89 (1997) 629-639
40. Donoviel D.B., Hadjantonakis A.K., Ikeda M., Zheng H., Hyslop P.S., and Bernstein A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev. 13 (1999) 2801-2810
41. Zhao B., Yu M., Neitzel M., Marugg J., Jagodzinski J., Lee M., Hu K., Schenk D., Yednock T., and Basi G. Identification of gamma-secretase inhibitor potency determinants on Presenilin. J. Biol. Chem. 10 (2007) 1074/jbc.M708870200
42. Shen J., and Kelleher R.J. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 403-409
43. Wolfe M.S. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 8 (2007) 136-140
44. De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 8 (2007) 141-146